A 52-year-old postmenopausal woman from Delhi presents with a 3-month history of a painless, hard lump in the upper outer quadrant of her left breast. On examination, the mass is 2 cm, fixed to the chest wall, and there is skin dimpling. Axillary lymph nodes are palpable and firm. Mammography shows a dense, irregular mass with microcalcifications. Core needle biopsy reveals infiltrating ductal carcinoma (IDC) with intermediate nuclear grade and 8 mitoses per 10 high-power fields. Immunohistochemistry shows ER+, PR+, HER2 negative (1+ by IHC). What is the most important prognostic factor among those identified in this case?

Explanation

## Prognostic Factors in Breast Carcinoma **Key Point:** Lymph node status is the single most important prognostic factor in breast cancer. The presence of axillary lymph node metastases significantly reduces 5-year survival and guides adjuvant therapy decisions. ### Prognostic Hierarchy in Breast Cancer | Factor | Prognostic Impact | Comment | |--------|-------------------|----------| | **Lymph node status** | Most important | Presence/absence and number of involved nodes determine stage and survival | | Tumor size | Very important | Directly correlates with risk of metastasis | | Histological grade | Important | Reflects cellular differentiation and aggressiveness | | Hormone receptor status | Important | Predicts response to endocrine therapy, not primary prognosis | | HER2 status | Important | Predicts response to targeted therapy (trastuzumab) | | Histological type | Moderate | IDC is most common; special types (tubular, mucinous) have better prognosis | | Microcalcifications | Diagnostic aid | Helps detect cancer on imaging, not a prognostic marker | **High-Yield:** The TNM staging system places **N (node status)** as the most critical component after T (tumor size). Node-positive disease (N1–N3) dramatically worsens prognosis compared to node-negative (N0). ### Why Lymph Node Status Dominates 1. **Reflects dissemination:** Nodal involvement indicates the tumor's metastatic potential. 2. **Guides adjuvant therapy:** Node-positive patients receive systemic chemotherapy regardless of other factors. 3. **Survival impact:** 5-year survival for N0 disease ≈ 85–90%; for N1 ≈ 65–75%; for N3 ≈ 40–50%. **Clinical Pearl:** Even a small (T1) tumor with positive nodes (N1) is more serious than a large (T3) node-negative tumor. This is why sentinel lymph node biopsy is standard of care. **Warning:** Hormone receptor positivity (ER+/PR+) is a **favorable prognostic factor** but does NOT override the adverse effect of lymph node involvement. It predicts response to endocrine therapy, not inherent prognosis.